Effectiveness, persistence and safety of E/C/F/TAF, F/TAF+3rd agent or R/F/TAF in treatment-experienced HIV-1 infected patients: 12-month results from the German TAFNES cohort study

被引：0
|
作者：
Hillenbrand, H. [1 ]
Knechten, H. [2 ]
Kuemmerle, T. [3 ]
Scholten, S. [4 ]
Schuebel, N. [5 ]
Haubrich, R. [6 ]
Heinzkill, M. [7 ]
Goerner, K. [7 ]
Stellbrink, H. [8 ]
机构：
[1] MVZ Praxis City Ost, Clin Care, Berlin, Germany
[2] Praxis Dr Knechten, Clin Care, Aachen, Germany
[3] Praxis Ebertplatz, Clin Care, Cologne, Germany
[4] Praxis Hohenstaufenring, Cologne, Germany
[5] Klinikum Osnabruck, Clin Care, Osnabruck, Germany
[6] Gilead Sci, Clin Sci, Foster City, CA USA
[7] Gilead Sci, Clin Sci, Munich, Germany
[8] ICH Study Ctr, Clin Care, Hamburg, Germany
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P069
引用
收藏
页数：2
相关论文
共 37 条
  • [1] Effectiveness, persistence and safety of E/C/F/TAF, F/TAF+3rd agent or R/F/TAF use in treatment-naive HIV-1 infected patients: 12-month results from the German TAFNES cohort study
    Heuchel, T.
    Hillenbrand, H.
    Jessen, H.
    Pauli, R.
    Postel, N.
    Haubrich, R.
    Heinzkill, M.
    Goerner, K.
    Stellbrink, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [2] 24-month evaluation of the German TAFNES cohort - Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-experienced HIV-1 infected patients
    Knechten, H.
    Schneeweiss, S.
    Schuebel, N.
    Hillenbrand, H.
    Kuemmerle, T.
    Schreiber, S.
    Goerner, K.
    Heinzkill, M.
    Haubrich, R.
    Stellbrink, H-J
    [J]. HIV MEDICINE, 2019, 20 : 60 - 61
  • [3] Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naive HIV-1 infected patients-24-month results from the German TAFNES cohort study
    Pauli, R.
    Jessen, H.
    Postel, N.
    Heuchel, T.
    Rieke, A.
    Hillenbrand, H.
    Kuemmerle, T.
    Schreiber, S.
    Goerner, K.
    Heinzkill, M.
    Haubrich, R.
    Stellbrink, H-J
    [J]. HIV MEDICINE, 2019, 20 : 54 - 55
  • [4] Effectiveness and persistence of E/C/F/TAF, R/F/TAF or F/TAF+3rd agent in late and very late presenters-final 24 month results from the German TAFNES cohort study
    Postel, Nils
    Jessen, Heiko
    Pauli, Ramona
    Hillenbrand, Heribert
    Rieke, Ansgar
    Knechten, Heribert
    Stellbrink, Hans-Juergen
    Emmerich, Claudia
    Schreiber, Sandra
    Mack, Frank
    Haubrich, Richard
    [J]. INFECTION, 2021, 49 (SUPPL 1) : S16 - S17
  • [5] Effectiveness and persistence of F/TAF-containing regimens (E/C/F/TAF, R/F/TAF or F/TAF+3rd agent) in late and very late presenters: final 24-month results from the German TAFNES cohort study
    Postel, N.
    Jessen, H.
    Pauli, R.
    Hillenbrand, H.
    Heuchel, T.
    Rieke, A.
    Knechten, H.
    Emmerich, C.
    Schreiber, S.
    Mack, F.
    Haubrich, R.
    Stellbrink, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 108 - 109
  • [6] Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), rilpivirine/F/TAF (R/F/TAF) or F/TAF + another 3rd agent in HIV-1+patients over 24 months - Results from the German TAFNES cohort study
    Stellbrink, H.
    Scholten, S.
    Hillenbrand, H.
    Knechten, H.
    Jessen, H.
    Schreiber, S.
    Goerner, K.
    Haubrich, R.
    Heinzkill, M.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 54 - 55
  • [7] Effectiveness, persistence and safety in treatment-naive and treatment-experienced HIV-1 infected patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)-12-month evaluation of the French TARANIS cohort
    Meynard, J-L
    Duvivier, C.
    Molina, J-M
    Ajana, F.
    Pichancourt, G.
    Morlat, P.
    Revest, M.
    Poizot-Martin, I.
    Hocqueloux, L.
    Janssen, C.
    Genet, P.
    Katlama, C.
    Leclercq, P.
    Haubrich, R.
    Ramroth, H.
    Durand, F.
    Sahali, S.
    [J]. HIV MEDICINE, 2019, 20 : 59 - 60
  • [8] Impact of baseline comorbidities on ART persistence and effectiveness in PLWH receiving F/TAF-based regimens: final 24-month results from the German TAFNES cohort study
    Scholten, S.
    Hillenbrand, H.
    Postel, N.
    Knechten, H.
    Pauli, R.
    Jessen, H.
    Emmerich, C.
    Pehlivan, C.
    Albuquerque, B.
    Haubrich, R.
    Stellbrink, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 67 - 68
  • [9] The effectiveness of E/C/F/TAF in treatment-naive (TN) or treatment-experienced (TE) adult HIV-infected patients in a real-world setting, results from southern Turkey
    Inan, D.
    Ulu, A. Candevir
    Yildirim, F. Sarigul
    Ersoz, G.
    Komur, S.
    User, U.
    Kandemir, O.
    Kuscu, F.
    Cuvalci, N. Oztoprak
    Inal, A. S.
    Celen, M. K.
    Saba, R.
    Kurtaran, B.
    Tasova, Y.
    [J]. HIV MEDICINE, 2019, 20 : 82 - 83
  • [10] HIV-1/HCV Coinfection Treatment with Single-Tablet Antiviral Regimens (CoSTARs): 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) after Randomized Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Rilpivirine/F/TAF (R/F/TAF)
    Ramgopal, Moti
    Jain, Mamta K.
    Hinestrosa, Federico
    Asmuth, David
    Huhn, Gregory
    Slim, Jihad
    Goldstein, Deborah
    Ryu, Julie
    Jiang, Shuping
    Das, Moupali
    Piontkowsky, David
    Rossaro, Lorenzo
    Haubrich, Richard
    Nguyen-Cleary, Thai
    [J]. HEPATOLOGY, 2017, 66 (06) : 1262A - 1263A
1234